288 related articles for article (PubMed ID: 32416207)
1. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Wan MT; Shin DB; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Aug; 83(2):677-679. PubMed ID: 32416207
[No Abstract] [Full Text] [Related]
2. The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Syed MN; Shin DB; Wan MT; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Nov; 83(5):1523-1526. PubMed ID: 32622891
[No Abstract] [Full Text] [Related]
3. COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.
Carugno A; Gambini DM; Raponi F; Vezzoli P; Locatelli AGC; Di Mercurio M; Robustelli Test E; Sena P
J Am Acad Dermatol; 2020 Jul; 83(1):292-294. PubMed ID: 32387660
[No Abstract] [Full Text] [Related]
4. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.
Georgakopoulos JR; Mufti A; Vender R; Yeung J
J Am Acad Dermatol; 2020 Oct; 83(4):1212-1214. PubMed ID: 32679279
[No Abstract] [Full Text] [Related]
5. Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
Megna M; Fabbrocini G; Marasca C
Int J Dermatol; 2020 Sep; 59(9):1144-1145. PubMed ID: 32710548
[No Abstract] [Full Text] [Related]
6. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Gisondi P; Facheris P; Dapavo P; Piaserico S; Conti A; Naldi L; Cazzaniga S; Malagoli P; Costanzo A
Br J Dermatol; 2020 Aug; 183(2):373-374. PubMed ID: 32343839
[No Abstract] [Full Text] [Related]
7. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.
Kearns DG; Uppal S; Chat VS; Wu JJ
J Am Acad Dermatol; 2020 Sep; 83(3):e251-e252. PubMed ID: 32534081
[No Abstract] [Full Text] [Related]
8. Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.
Sanchez DP; Kirsner RS; Lev-Tov H
J Am Acad Dermatol; 2020 Jul; 83(1):288-292. PubMed ID: 32380214
[No Abstract] [Full Text] [Related]
9. [Not Available].
Nau JY
Rev Med Suisse; 2020 Jun; 16(696):1174-1175. PubMed ID: 32496708
[No Abstract] [Full Text] [Related]
10. Keeping track of the SARS-CoV-2 vaccine pipeline.
Parker EPK; Shrotri M; Kampmann B
Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
[TBL] [Abstract][Full Text] [Related]
11. Will bacille Calmette-Guerin immunization arrest the COVID-19 pandemic?
Ehtesham NZ; Samal J; Ahmad F; Arish M; Naz F; Alam A; Agrawal U; Hasnain SE
Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):16-20. PubMed ID: 32859863
[No Abstract] [Full Text] [Related]
12. Understanding COVID-19 vaccine efficacy.
Lipsitch M; Dean NE
Science; 2020 Nov; 370(6518):763-765. PubMed ID: 33087460
[No Abstract] [Full Text] [Related]
13. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
Blaszczak A; Trinidad JCL; Cartron AM
J Am Acad Dermatol; 2020 Jul; 83(1):e31. PubMed ID: 32283230
[No Abstract] [Full Text] [Related]
14. Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?
Chu C; Sun Y; Pan Y
Oral Oncol; 2020 Aug; 107():104860. PubMed ID: 32571643
[No Abstract] [Full Text] [Related]
15. Developing Covid-19 Vaccines at Pandemic Speed.
Lurie N; Saville M; Hatchett R; Halton J
N Engl J Med; 2020 May; 382(21):1969-1973. PubMed ID: 32227757
[No Abstract] [Full Text] [Related]
16. Coronavirus vaccines get a biotech boost.
Dance A
Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
[No Abstract] [Full Text] [Related]
17. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.
Gisondi P; Zaza G; Del Giglio M; Rossi M; Iacono V; Girolomoni G
J Am Acad Dermatol; 2020 Jul; 83(1):285-287. PubMed ID: 32330632
[No Abstract] [Full Text] [Related]
18. Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Mahil SK; Yiu ZZN; Mason KJ; Dand N; Coker B; Wall D; Fletcher G; Bosma A; Capon F; Iversen L; Langan SM; Di Meglio P; Musters AH; Prieto-Merino D; Tsakok T; Warren RB; Flohr C; Spuls PI; Griffiths CEM; Barker J; Irvine AD; Smith CH;
Br J Dermatol; 2020 Aug; 183(2):404-406. PubMed ID: 32348554
[No Abstract] [Full Text] [Related]
19. The Race to Develop a COVID-19 Vaccine.
Am J Nurs; 2020 Oct; 120(10):14-15. PubMed ID: 32976132
[TBL] [Abstract][Full Text] [Related]
20. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
Kearns DG; Chat VS; Uppal S; Wu JJ
J Am Acad Dermatol; 2020 Dec; 83(6):e433-e434. PubMed ID: 32735966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
